ERBB2 and breast carcinoma: Moreover, clinical data showed that the addition of anti-estrogen receptor drugs in the treatment regimen of HER2+/HR+ breast cancer did not provide additional advantages in the pCR rates and DFS (Harbeck et al., 2017; Rimawi et al., 2017).